Sihuan Pharmaceutical Holdings Group Ltd (460.HK) stock: key figures, P/E, revenue and dividend

Health Care · China · ISIN BMG8162K1137

Price
0.62 HKD
Market cap
5.61 bn HKD
P/E (2025)
26.82
P/S (2025)
2.14
Dividend yield
1.51 %
Net margin
6.86 %
Return on equity (ROE)
2.60 %
Return on assets (ROA)
1.54 %

Sihuan Pharmaceutical Holdings Group Ltd financials

Fiscal year20242025
Revenue1.90 bn CNY2.62 bn CNY
Gross profit1.24 bn CNY2.10 bn CNY
EBIT-389.00 m CNY707.00 m CNY
Net income-216.00 m CNY179.70 m CNY
Diluted EPS – continuing operations-0.02 CNY0.02 CNY

Full history since 2003, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Sihuan Pharmaceutical Holdings Group Ltd

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China, the United States, and internationally. It operates in three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic devices, body sculpturing, skin care, and other services, as well as non- or minimally invasive comprehensive medical aesthetics solutions. It also provides drugs for cardio-cerebral vascular, digestive system, anti-infective, metabolism, respiratory, neurology, oncology, diabetes, and other indications, as well as modern Chinese medicine and industrial hemp products. In addition, the company offers general hospital services. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.